J&J and Pfizer Navigate Growth and Patent Challenges in 2026

Johnson & Johnson (JNJ) and Pfizer (PFE) are two of the largest healthcare companies, both with strong positions in oncology and other key therapeutic areas. J&J benefits from a diversified business model, including pharmaceuticals and medical devices, which helps it weather economic challenges. Its Innovative Medicine segment drove a 6.2% organic sales increase in the first half of 2026, led by drugs like Darzalex and Tremfya, along with new products such as Carvykti and Tecvayli. Despite some softness in its MedTech division, particularly in Cardiovascular, J&J remains optimistic about achieving over $100 billion in revenues for 2026 and aims for double-digit growth by the end of the decade.

Pfizer, on the other hand, has transitioned from heavy COVID-19 product dependency to a diversified portfolio through internal launches and strategic acquisitions like Seagen and Metsera. Its oncology revenues grew 5% in the first half of 2026, with drugs like Padcev and Xtandi leading the charge. Pfizer is also investing in obesity treatments and oncology pipelines, targeting approvals for berobenatide by 2028. However, the company faces a significant patent cliff later this decade, which is expected to reduce sales by approximately $1.1 billion in 2026.

Analysts project a 7.4% year-over-year sales increase for J&J in 2026, while Pfizer’s sales are expected to decrease slightly. J&J’s stock has risen 23.7% year-to-date, outperforming Pfizer’s 11.7% gain. From a valuation perspective, Pfizer appears more attractive, but both companies offer strong dividend yields and growth potential in their respective segments.